AWM Investment Company Inc. Continues to Hold Position in Opko Health, Inc. (OPK)

AWM Investment Company Inc. continued to hold its position in Opko Health, Inc. (NASDAQ:OPK) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 350,000 shares of the biotechnology company’s stock at the end of the first quarter. AWM Investment Company Inc. owned 0.06% of Opko Health worth $2,800,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. UBS Group AG boosted its position in Opko Health by 56.4% in the first quarter. UBS Group AG now owns 778,224 shares of the biotechnology company’s stock valued at $6,226,000 after buying an additional 280,500 shares during the period. Dimensional Fund Advisors LP boosted its position in Opko Health by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,621,128 shares of the biotechnology company’s stock valued at $12,968,000 after buying an additional 31,225 shares during the period. Old West Investment Management LLC boosted its position in Opko Health by 12.0% in the first quarter. Old West Investment Management LLC now owns 40,046 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 4,305 shares during the period. Geode Capital Management LLC boosted its position in Opko Health by 7.9% in the first quarter. Geode Capital Management LLC now owns 2,889,059 shares of the biotechnology company’s stock valued at $23,111,000 after buying an additional 210,736 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its position in Opko Health by 1.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 503,931 shares of the biotechnology company’s stock valued at $4,031,000 after buying an additional 6,315 shares during the period. 23.65% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Opko Health, Inc. (OPK) traded up 1.67% during mid-day trading on Tuesday, hitting $6.70. The stock had a trading volume of 3,875,024 shares. Opko Health, Inc. has a one year low of $5.99 and a one year high of $12.15. The firm’s market capitalization is $3.75 billion. The stock’s 50 day moving average price is $6.73 and its 200 day moving average price is $8.30.

Opko Health (NASDAQ:OPK) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.02. The company had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. Opko Health’s revenue was up 1.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.02) earnings per share. Analysts forecast that Opko Health, Inc. will post ($0.20) EPS for the current year.

WARNING: This article was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://sportsperspectives.com/2017/06/20/awm-investment-company-inc-has-2800000-position-in-opko-health-inc-opk-updated.html.

OPK has been the subject of several research reports. Jefferies Group LLC reduced their price target on Opko Health from $10.00 to $8.00 and set a “hold” rating for the company in a report on Thursday, March 2nd. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a report on Friday, March 3rd. Standpoint Research restated a “buy” rating and issued a $14.00 target price on shares of Opko Health in a report on Sunday, March 5th. Guggenheim began coverage on Opko Health in a report on Tuesday, March 14th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $19.50 target price on shares of Opko Health in a report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.58.

In other Opko Health news, CEO Phillip Md Et Al Frost purchased 207,700 shares of the stock in a transaction dated Wednesday, May 31st. The stock was purchased at an average price of $6.11 per share, with a total value of $1,269,047.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $18,751,290.61. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Vice Chairman Jane Ph D. Hsiao purchased 40,000 shares of the stock in a transaction dated Wednesday, May 10th. The stock was acquired at an average cost of $6.97 per share, with a total value of $278,800.00. Following the transaction, the insider now directly owns 24,723,133 shares in the company, valued at approximately $172,320,237.01. The disclosure for this purchase can be found here. Insiders acquired a total of 2,681,200 shares of company stock worth $18,331,123 over the last 90 days. Insiders own 40.74% of the company’s stock.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply